These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26596282)

  • 61. The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption.
    Turner AG; Tjahyono F; Chiu WS; Skinner J; Sawyer R; Moore AJ; Morris HA; Findlay DM; Zajac JD; Davey RA
    Bone; 2011 Feb; 48(2):354-61. PubMed ID: 20850575
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane.
    Schmidt MC; Rothen-Rutishauser B; Rist B; Beck-Sickinger A; Wunderli-Allenspach H; Rubas W; Sadée W; Merkle HP
    Biochemistry; 1998 Nov; 37(47):16582-90. PubMed ID: 9843425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Substance P regulates the function of rabbit cultured osteoclast; increase of intracellular free calcium concentration and enhancement of bone resorption.
    Mori T; Ogata T; Okumura H; Shibata T; Nakamura Y; Kataoka K
    Biochem Biophys Res Commun; 1999 Aug; 262(2):418-22. PubMed ID: 10462490
    [TBL] [Abstract][Full Text] [Related]  

  • 64. High extracellular calcium concentrations directly stimulate osteoclast apoptosis.
    Lorget F; Kamel S; Mentaverri R; Wattel A; Naassila M; Maamer M; Brazier M
    Biochem Biophys Res Commun; 2000 Feb; 268(3):899-903. PubMed ID: 10679302
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Heme prevents highly amyloidogenic human calcitonin (hCT) aggregation: A potential new strategy for the clinical reuse of hCT.
    Ye H; Zhou J; Li H; Gao Z
    J Inorg Biochem; 2019 Jul; 196():110686. PubMed ID: 31003065
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Degradation and aggregation of human calcitonin in vitro.
    Lu RH; Kopecková P; Kopecek J
    Pharm Res; 1999 Mar; 16(3):359-67. PubMed ID: 10213365
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of parathyroid hormone and calcitonin on osteoclast formation in vitro.
    Feldman RS; Krieger NS; Tashjian AH
    Endocrinology; 1980 Oct; 107(4):1137-43. PubMed ID: 7408763
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term culture of disaggregated rat osteoclasts: inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP[107-139].
    Fenton AJ; Martin TJ; Nicholson GC
    J Cell Physiol; 1993 Apr; 155(1):1-7. PubMed ID: 8468357
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Calcitonin-induced change in serum calcium levels and its relationship to osteoclast morphology and number of calcitonin receptors.
    Ikegame M; Ejiri S; Ozawa H
    Bone; 2004 Jul; 35(1):27-33. PubMed ID: 15207738
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones.
    Chambers TJ; McSheehy PM; Thomson BM; Fuller K
    Endocrinology; 1985 Jan; 116(1):234-9. PubMed ID: 3880540
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tyrosine 12 of human calcitonin modulates its amyloid formation, membrane binding, and bioactivity.
    Hsieh IC; Chen TW; Chuang YP; Lai YJ; Tu LH
    Biochimie; 2022 Jun; 197():121-129. PubMed ID: 35240220
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inhibition of the fibrillation of highly amyloidogenic human calcitonin by cucurbit[7]uril with improved bioactivity.
    Shang H; Zhou A; Jiang J; Liu Y; Xie J; Li S; Chen Y; Zhu X; Tan H; Li J
    Acta Biomater; 2018 Sep; 78():178-188. PubMed ID: 30076991
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin.
    Bauer HH; Aebi U; Häner M; Hermann R; Müller M; Merkle HP
    J Struct Biol; 1995; 115(1):1-15. PubMed ID: 7577226
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations.
    Xie J; Guo J; Kanwal Z; Wu M; Lv X; Ibrahim NA; Li P; Buabeid MA; Arafa EA; Sun Q
    Int J Endocrinol; 2020; 2020():3236828. PubMed ID: 32963524
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Unraveling the underlying mechanisms of reduced amyloidogenic properties in human calcitonin via double mutations.
    Chang YP; Pan PC; Tu LH
    Protein Sci; 2024 Apr; 33(4):e4952. PubMed ID: 38501491
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dihydrocaffeic Acid-Decorated Iron Oxide Nanomaterials Effectively Inhibit Human Calcitonin Aggregation.
    Shen CL; Wu YH; Zhang TH; Tu LH
    ACS Omega; 2022 Sep; 7(35):31520-31528. PubMed ID: 36092590
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Y12 nitration of human calcitonin (hCT): A promising strategy to produce non-aggregation bioactive hCT.
    Ye H; Li H; Gao Z
    Nitric Oxide; 2020 Nov; 104-105():11-19. PubMed ID: 32827754
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acetyl-[Asn30,Tyr32]-calcitonin fragment 8-32 forms channels in phospholipid planar lipid membranes.
    Meleleo D; Gallucci E; Picciarelli V; Micelli S
    Eur Biophys J; 2007 Sep; 36(7):763-70. PubMed ID: 17393160
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human calcitonin.
    Kuhlencordt F; Lozano-Tonkin C
    Lancet; 1969 Mar; 1(7596):679. PubMed ID: 4179915
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.